Recently, two novel anti-CD19 monoclonal antibodies have been approved by the FDA, namely tafasitamab and loncastuximab tesirine, which have been propagated as viable options for the treatment of R/R diffuse large B-cell lymphoma (DLBCL); however, further studies are required to evaluate the infectious complications of these therapies [96]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.